AU2016296321B2 - Anti-TfR antibodies and their use in treating proliferative and inflammatory disorders - Google Patents

Anti-TfR antibodies and their use in treating proliferative and inflammatory disorders Download PDF

Info

Publication number
AU2016296321B2
AU2016296321B2 AU2016296321A AU2016296321A AU2016296321B2 AU 2016296321 B2 AU2016296321 B2 AU 2016296321B2 AU 2016296321 A AU2016296321 A AU 2016296321A AU 2016296321 A AU2016296321 A AU 2016296321A AU 2016296321 B2 AU2016296321 B2 AU 2016296321B2
Authority
AU
Australia
Prior art keywords
antibody
seq
ser
protein
tfr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016296321A
Other languages
English (en)
Other versions
AU2016296321A1 (en
Inventor
Coralie BELANGER
Pierre Launay
Hervé Souchet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inatherys
Original Assignee
Inatherys
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inatherys filed Critical Inatherys
Publication of AU2016296321A1 publication Critical patent/AU2016296321A1/en
Application granted granted Critical
Publication of AU2016296321B2 publication Critical patent/AU2016296321B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2016296321A 2015-07-22 2016-07-21 Anti-TfR antibodies and their use in treating proliferative and inflammatory disorders Active AU2016296321B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15306192.4 2015-07-22
EP15306192 2015-07-22
PCT/EP2016/067465 WO2017013230A1 (en) 2015-07-22 2016-07-21 ANTI-TfR ANTIBODIES AND THEIR USE IN TREATING PROLIFERATIVE AND INFLAMMATORY DISORDERS

Publications (2)

Publication Number Publication Date
AU2016296321A1 AU2016296321A1 (en) 2018-01-25
AU2016296321B2 true AU2016296321B2 (en) 2022-09-08

Family

ID=53776520

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016296321A Active AU2016296321B2 (en) 2015-07-22 2016-07-21 Anti-TfR antibodies and their use in treating proliferative and inflammatory disorders

Country Status (22)

Country Link
US (2) US11230605B2 (enExample)
EP (1) EP3325509B1 (enExample)
JP (1) JP6858185B2 (enExample)
KR (1) KR102690998B1 (enExample)
CN (1) CN107849136B (enExample)
AU (1) AU2016296321B2 (enExample)
CA (1) CA2992509C (enExample)
CY (1) CY1123941T1 (enExample)
DK (1) DK3325509T3 (enExample)
ES (1) ES2860988T3 (enExample)
HR (1) HRP20210393T1 (enExample)
HU (1) HUE053296T2 (enExample)
IL (1) IL257065B (enExample)
LT (1) LT3325509T (enExample)
MX (1) MX2018000569A (enExample)
PL (1) PL3325509T3 (enExample)
PT (1) PT3325509T (enExample)
RS (1) RS61586B1 (enExample)
RU (1) RU2737637C2 (enExample)
SI (1) SI3325509T1 (enExample)
SM (1) SMT202100134T1 (enExample)
WO (1) WO2017013230A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI787796B (zh) 2015-05-04 2022-12-21 美商Ｃｙｔｏｍｘ生物製藥公司 抗ｃｄ７１抗體類、可活化之抗ｃｄ７１抗體類及使用彼等之方法
FR3062213B1 (fr) 2017-01-20 2021-02-26 Endodiag Utilisation du recepteur cd71 dans la detection et le traitement de l’endometriose
EP3552631A1 (en) * 2018-04-10 2019-10-16 Inatherys Antibody-drug conjugates and their uses for the treatment of cancer
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US12370264B1 (en) 2018-08-02 2025-07-29 Dyne Therapeutics, Inc. Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
EP3830259A4 (en) 2018-08-02 2022-05-04 Dyne Therapeutics, Inc. MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
WO2020028832A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12595310B2 (en) 2019-11-06 2026-04-07 The Regents Of The University Of California Compositions and methods for transferrin receptor 1 targeting
IL295022A (en) * 2020-01-31 2022-09-01 Dyne Therapeutics Inc Antibody against transferrin receptor and uses thereof
WO2021154477A1 (en) 2020-01-31 2021-08-05 Dyne Therapeutics, Inc. Anti-transferrin receptor (tfr) antibody and uses thereof
US12629426B2 (en) * 2020-07-23 2026-05-19 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11672872B2 (en) 2021-07-09 2023-06-13 Dyne Therapeutics, Inc. Anti-transferrin receptor antibody and uses thereof
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11638761B2 (en) * 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11969475B2 (en) * 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
WO2023283623A1 (en) 2021-07-09 2023-01-12 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating dystrophinopathies
CA3230796A1 (en) 2021-09-01 2023-03-09 Biogen Ma Inc. Anti-transferrin receptor antibodies and uses thereof
TW202330601A (zh) * 2021-09-13 2023-08-01 德州大學系統董事會 ＴｆＲ抗原結合蛋白及其用途
IL316143A (en) * 2022-04-15 2024-12-01 Dyne Therapeutics Inc Muscle targeting complexes and formulations for the treatment of myotonic dystrophy
KR20250114322A (ko) * 2022-12-02 2025-07-29 바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 항-tfr1 항체 및 이의 용도
TW202444759A (zh) 2023-03-24 2024-11-16 美商戴納立製藥公司 Ａβ靶向蛋白及使用方法
EP4477236A1 (en) 2023-06-14 2024-12-18 Inatherys Combination therapy for treating a tumor using adc comprising anti-cd71 antibodies and bh3 mimetics
IL327952A (en) * 2023-10-26 2026-06-01 Biogen Ma Inc Anti-transferrin receptor antibodies and uses thereof
WO2025140522A1 (en) * 2023-12-29 2025-07-03 Nona Biosciences (Suzhou) Co., Ltd. Anti-tfr1 antibodies, preparation methods and uses thereof
CN121517563A (zh) * 2024-08-09 2026-02-13 东北制药集团股份有限公司 人源化的靶向TfR1的抗体及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005111082A1 (en) * 2004-04-30 2005-11-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-tfr antibody.
WO2014020140A1 (en) * 2012-08-02 2014-02-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of transferrin receptor antagonist for the treatment of thalassemia

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4434156A (en) 1981-10-26 1984-02-28 The Salk Institute For Biological Studies Monoclonal antibodies specific for the human transferrin receptor glycoprotein
HUP0104865A3 (en) * 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
ES2369542T3 (es) 2002-07-31 2011-12-01 Seattle Genetics, Inc. Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
WO2005011082A2 (en) 2003-07-23 2005-02-03 Univeral Infusion Technology Drive motor transmission system
KR101295139B1 (ko) * 2004-06-07 2013-08-12 레이븐 바이오테크놀로지스, 인코퍼레이티드 트랜스페린 리셉터 항체
EP3530736A3 (en) * 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
FR2953841B1 (fr) * 2009-12-16 2011-12-30 Centre Nat Rech Scient Anticorps diriges contre le recepteur de la transferrine et leurs utilisations pour l'immunotherapie des tumeurs qui dependent du fer
DK2918603T3 (en) * 2012-11-08 2018-10-15 Univ Miyazaki ANTIBODY STANDING TO SPECIFICALLY RECOGNIZE TRANSFERRIN RECEPTOR
EP3552631A1 (en) * 2018-04-10 2019-10-16 Inatherys Antibody-drug conjugates and their uses for the treatment of cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005111082A1 (en) * 2004-04-30 2005-11-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-tfr antibody.
WO2014020140A1 (en) * 2012-08-02 2014-02-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of transferrin receptor antagonist for the treatment of thalassemia

Also Published As

Publication number Publication date
AU2016296321A1 (en) 2018-01-25
IL257065A (en) 2018-03-29
RU2018106364A (ru) 2019-08-22
RU2737637C2 (ru) 2020-12-01
MX2018000569A (es) 2018-09-27
PL3325509T3 (pl) 2021-07-19
EP3325509B1 (en) 2020-12-16
ES2860988T3 (es) 2021-10-05
LT3325509T (lt) 2021-06-10
CA2992509A1 (en) 2017-01-26
SMT202100134T1 (it) 2021-05-07
HUE053296T2 (hu) 2021-06-28
KR20180028519A (ko) 2018-03-16
US12037408B2 (en) 2024-07-16
DK3325509T3 (da) 2021-03-08
US11230605B2 (en) 2022-01-25
CN107849136A (zh) 2018-03-27
RS61586B1 (sr) 2021-04-29
WO2017013230A1 (en) 2017-01-26
HK1256088A1 (en) 2019-09-13
US20190092870A1 (en) 2019-03-28
JP6858185B2 (ja) 2021-04-14
CY1123941T1 (el) 2022-05-27
KR102690998B1 (ko) 2024-07-31
EP3325509A1 (en) 2018-05-30
HRP20210393T1 (hr) 2021-04-30
PT3325509T (pt) 2021-03-12
IL257065B (en) 2022-07-01
BR112018000650A2 (en) 2018-09-18
SI3325509T1 (sl) 2021-07-30
US20220119543A1 (en) 2022-04-21
RU2018106364A3 (enExample) 2019-08-22
CA2992509C (en) 2025-02-04
CN107849136B (zh) 2022-04-01
JP2018521691A (ja) 2018-08-09

Similar Documents

Publication Publication Date Title
US12037408B2 (en) Method of treating a tumor using anti-TfR antibodies
AU2020286284B2 (en) Novel anti-CD39 antibodies
AU2008232409B2 (en) Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind CD154 and uses thereof
CN109476742B (zh) Tl1a抗体及其用途
KR102847971B1 (ko) 항체-약물 컨쥬게이트 및 이의 암 치료 용도
IL268336A (en) Il-18 binding molecules
BR122020025629B1 (pt) Anticorpo anti-ox40, composição farmacêutica que compreende o mesmo e método in vitro para a produção do dito anticorpo
CA2934965A1 (en) Novel anti-baff antibodies
CN117794948A (zh) 结合人纤维蛋白或纤维蛋白原γC结构域的抗体及其使用方法
KR20160010391A (ko) Cd20 및 cd95에 결합하는 재조합 이중특이성 항체
US20250188163A1 (en) Gprc5d antibodies with enhanced effector function and uses thereof
US12606619B2 (en) Human monoclonal antibodies against TIGIT for immune related diseases
AU2022225091A1 (en) Antibodies that bind CD123 and gamma-delta T cell receptors
WO2024175030A1 (zh) 抗Nectin-4抗体和包含其的多特异性抗体
WO2024251154A1 (zh) 抗gprc5d/bcma/cd3三特异性抗体的制备及其用途
CA3254085A1 (en) KLRB1 LIAISON AGENTS AND THEIR METHODS OF USE
CN117295762A (zh) 抗cd122抗体及其用途
HK1256088B (en) Anti-tfr antibodies and their use in treating proliferative and inflammatory disorders
BR112018000650B1 (pt) Anticorpos anti-trf e sua utilização no tratamento de transtornos proliferativos e inflamatórios
CA3294164A1 (en) Preparation of anti-gprc5d/bcma/cd3 trispecific antibody and use thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)